E

system STAT Myoglobin

2K43
840268/R4

STAT Myoglobin
Customer Service
United States: 1-877-4ABBOTT
International: Call your Abbott Representative

This package insert must be read carefully prior to use. Package insert instructions must be followed.
Reliability of assay results cannot be guaranteed if there are any deviations from the instructions in
this package insert.

Read Highlighted Changes

Revised November, 2007

Key to symbols used

List Number Lot Number

In Vitro Diagnostic Medical

Device Expiration Date

Store at 2-8°C Reaction Vessels

Sample Cups
Consult instructions for use
Septum

Serial Number Replacement

Caps

Authorized Representative Reagent Lot

Assay CD-ROM
Manufacturer
Control Number

See REAGENTS section for a full explanation of symbols used in reagent

component naming.

1
NAME Other Reagents
ARCHITECT STAT Myoglobin ARCHITECT i Pre-Trigger Solution
INTENDED USE • Pre-Trigger Solution containing 1.32%
ARCHITECT STAT Myoglobin is a chemiluminescent microparticle (w/v) hydrogen peroxide.
immunoassay (CMIA) for the quantitative determination of myoglobin ARCHITECT i Trigger Solution
in human serum and plasma on the ARCHITECT i System with STAT • Trigger Solution containing 0.35 N sodium
protocol capability. Myoglobin values are used to assist in the diagnosis hydroxide.
of myocardial infarction (MI). ARCHITECT i Wash Buffer
SUMMARY AND EXPLANATION OF TEST • Wash Buffer containing phosphate buffered saline
Myoglobin is a tightly folded, globular heme-protein located in the solution. Preservative: antimicrobial agent.
cytoplasm of both skeletal and cardiac muscle cells. Its function is to store WARNINGS AND PRECAUTIONS
and supply oxygen to muscle cells. The molecular weight of myoglobin
For In Vitro Diagnostic Use.
is approximately 17,800 daltons.1,2 The relatively low molecular weight
and the location of storage accounts for the rapid release from damaged Safety Precautions
muscle cells and earlier rises in concentration measured above baseline • CAUTION: This product requires the handling of human specimens.
in blood as compared to other cardiac markers.1,3,4 It is recommended that all human sourced materials are considered
In ischemic heart disease, such as myocardial infarction (MI), a temporal potentially infectious and be handled in accordance with the OSHA
pattern of increased release of myoglobin into the blood stream Standard on Bloodborne Pathogens.8 Biosafety Level 29 or other
is observed. The serum or plasma myoglobin level will start to show appropriate biosafety practices10,11 should be used for materials that
an increase between 2-4 hours after an MI has occurred, peaking at contain or are suspected of containing infectious agents.
approximately 8-10 hours, and returning to baseline after 24 hours. • The ARCHITECT STAT Myoglobin Conjugate contains a mixture of:
Measurement of myoglobin between 2-12 hours after an MI can be a 5-chloro-2-methyl-4-isothiazolin-3-one and 2-methyl-4-isothiazolin-
good adjunct to electrocardiography (ECG) in improving the efficiency of 3-one (3:1), which is a component of ProClin, and is classified per
early diagnosis of MI.1,5,6 Monitoring the myoglobin levels can also help applicable European Community (EC) Directives as: Irritant (Xi). The
in evaluating the success of thrombolytic therapy.6,7 following are the appropriate Risk (R) and Safety (S) phrases:
Since myoglobin is present in both cardiac and skeletal muscle, any R43 May cause sensitization by skin contact.
damage to either of these muscle types results in its release into the S24 Avoid contact with skin.
blood stream. Elevated serum levels of myoglobin have been observed S35 This material and its container must be
under the following conditions: skeletal muscle damage, skeletal muscle disposed of in a safe way.
or neuromuscular disorders, cardiac bypass surgery, renal failure,
strenuous exercise.2,5 Therefore, serum myoglobin levels should be used S37 Wear suitable gloves.
in conjunction with other aspects of the patient assessment to aid in S46 If swallowed, seek medical advice
the diagnosis of an MI. Myoglobin may also rise moderately above the immediately and show this container or label.
reference range in chronic ischemic heart disease (i.e. unstable angina).2
• This product contains sodium azide; for a specific listing, refer to the
For diagnostic purposes, the ARCHITECT STAT Myoglobin assay results
REAGENTS section. Contact with acids liberates very toxic gas. This
should be used in conjunction with other data; e.g., other clinical testing,
material and its container must be disposed of in a safe way.
ECG, symptoms, clinical observations.
• For product not classified as dangerous per European Directive
BIOLOGICAL PRINCIPLES OF THE PROCEDURE 1999/45/EC as amended - Safety data sheet available for
The ARCHITECT STAT Myoglobin assay is a two-step immunoassay for professional user on request.
the quantitative determination of myoglobin in human serum and plasma • For information on the safe disposal of sodium azide and a detailed
using CMIA technology with flexible assay protocols, referred to as discussion of safety precautions during system operation, refer to
Chemiflex. the ARCHITECT System Operations Manual, Section 8.
In the first step, sample and anti-myoglobin coated paramagnetic
Handling Precautions
microparticles are combined and incubated. Myoglobin present in the
sample binds to the anti-myoglobin coated microparticles. After washing, • Do not use reagent kits beyond the expiration date.
anti-myoglobin acridinium-labeled conjugate is added in the second step. • Do not pool reagents within a kit or between reagent kits.
Following another incubation and wash, pre-trigger and trigger solutions • Before loading the ARCHITECT STAT Myoglobin Reagent Kit on the
are added to the reaction mixture. The resulting chemiluminescent system for the first time, the microparticle bottle requires mixing to
reaction is measured as relative light units (RLUs). A direct relationship resuspend microparticles that have settled during shipment. For
exists between the amount of myoglobin in the sample and the RLUs microparticle mixing instructions, refer to the PROCEDURE, Assay
detected by the ARCHITECT i* System optics. Procedure section of this package insert.
For additional information on system and assay technology, refer to the • Septums MUST be used to prevent reagent evaporation and
ARCHITECT System Operations Manual, Section 3. contamination and to ensure reagent integrity. Reliability of assay
* i = immunoassay results cannot be guaranteed if septums are not used according
to the instructions in this package insert.
REAGENTS • To avoid contamination, wear clean gloves when placing a septum
Reagent Kit, 100 Tests/500 Tests on an uncapped reagent bottle.
NOTE: Some kit sizes are not available in all countries or for use on all • Prior to placing the septum on an uncapped reagent bottle, squeeze
ARCHITECT i Systems. Please contact your local distributor. the septum in half to confirm that the slits are open. If the slits appear
ARCHITECT STAT Myoglobin Reagent Kit (2K43) sealed, continue to gently squeeze the septum to open the slits.
• 1 or 4 Bottles (6.6 mL/27.0 mL) Anti-myoglobin • Once a septum has been placed on an open reagent bottle, do
(mouse, monoclonal) coated microparticles in TRIS buffer with not invert the bottle as this will result in reagent leakage and may
protein (bovine) stabilizer. Preservative: antimicrobial agents. compromise assay results.
• 1 or 4 Bottles (5.9 mL/26.3 mL) Anti-myoglobin • Over time, residual liquids may dry on the septum surface. These are
(mouse, monoclonal) acridinium-labeled conjugate in MES buffer typically dried salts which have no effect on assay efficacy.
with protein (bovine) stabilizer. Preservative: ProClin 300.
• For a detailed discussion of handling precautions during system
• 1 or 4 Bottles (10.0 mL/50.9 mL) Myoglobin operation, refer to the ARCHITECT System Operations Manual,
Specimen Diluent containing protein (bovine) stabilizer in TRIS
Section 7.
buffer. Preservative: sodium azide.

2
Storage Instructions • Use caution when handling patient specimens to prevent cross
contamination. Use of disposable pipettes or pipette tips is
recommended.
• The ARCHITECT STAT Myoglobin Reagent Kit must be • Inspect all samples for bubbles. Remove bubbles with an applicator
stored at 2-8°C in an upright position and may be used immediately stick prior to analysis. Use a new applicator stick for each sample to
after removal from 2-8°C storage. prevent cross contamination.
• When stored and handled as directed, reagents are stable until the • Plasma and serum specimens should be free of fibrin, red blood
expiration date. cells or other particulate matter.
• The ARCHITECT STAT Myoglobin Reagent Kit may be stored on • Ensure that complete clot formation in serum specimens has taken
board the ARCHITECT i System with STAT protocol capability for place prior to centrifugation. Some specimens, especially those
a maximum of 30 days. After 30 days, the reagent kit must be from patients receiving anticoagulant or thrombolytic therapy, may
discarded. For information on tracking onboard time, refer to the exhibit increased clotting time. If the specimen is centrifuged before
ARCHITECT System Operations Manual, Section 5. a complete clot forms, the presence of fibrin may cause erroneous
• Reagents may be stored on or off the ARCHITECT i System. If results.
reagents are removed from the system, store them at 2-8°C (with • Patient specimens with a cloudy or turbid appearance must be
septums and replacement caps) in an upright position. For reagents centrifuged prior to testing. Following centrifugation, avoid the lipid
stored off the system, it is recommended that they be stored layer (if present) when pipetting the specimen into a sample cup or
in their original trays and boxes to ensure they remain upright. If secondary tube.
the microparticle bottle does not remain upright (with a septum Preparation for Analysis
installed) while in refrigerated storage off the system, the reagent
• Follow the manufacturer’s processing instructions for plasma or
kit must be discarded. After reagents are removed from the system,
serum collection tubes.
initiate a reagent scan to update the onboard stability timer.
• Specimens must be mixed THOROUGHLY after thawing by LOW
Indications of Reagent Deterioration speed vortexing or by gently inverting, and centrifuged prior to use to
When a control value is out of the specified range, it may indicate remove red blood cells or particulate matter to ensure consistency
deterioration of the reagents or errors in technique. Associated test in the results. Multiple freeze-thaw cycles of specimens should be
results are invalid and must be retested. Assay recalibration may be avoided.
necessary. For troubleshooting information, refer to the ARCHITECT
Storage
System Operations Manual, Section 10.
• If testing will be delayed for more than 8 hours, remove plasma or
INSTRUMENT PROCEDURE serum from the serum or plasma separator, red blood cells or clot.
• The ARCHITECT STAT Myoglobin assay file must be installed on Specimens removed from the separator gel, cells or clot may be
the ARCHITECT i System with STAT protocol capability from the stored up to 72 hours at 2-8°C.
ARCHITECT i Assay CD-ROM Addition B before performing the • Specimens can be stored up to 30 days frozen at -10°C or colder.
assay. For detailed information on assay file installation and on • All samples (patient specimens, controls, and calibrators) should
viewing and editing assay parameters, refer to the ARCHITECT be tested within 3 hours of being placed on board the ARCHITECT
System Operations Manual, Section 2. System. Refer to the ARCHITECT System Operations Manual,
• For information on printing assay parameters, refer to the ARCHITECT Section 5, for a more detailed discussion of onboard sample storage
System Operations Manual, Section 5. constraints.
• For a detailed description of system procedures, refer to the
Shipping
ARCHITECT System Operations Manual.
• Before shipping specimens, it is recommended that specimens be
• The default result unit for the ARCHITECT STAT Myoglobin assay is removed from the serum or plasma separator, red blood cells or
ng/mL. An alternate result unit, μg/L, may be selected for reporting clot. When shipped, specimens must be packaged and labeled
results by editing assay parameter “Result concentration units” to in compliance with applicable state, federal and international
μg/L. The conversion factor used by the system is 1.0. regulations covering the transport of clinical specimens and
SPECIMEN COLLECTION AND PREPARATION FOR ANALYSIS infectious substances. Specimens must be shipped frozen (dry ice).
• The following specimen collection tubes may be used in the Do not exceed the storage time limitations identified in this section
ARCHITECT STAT Myoglobin assay. of the package insert.
Specimen Types PROCEDURE
Glass Plastic Materials Provided
Serum • No Additive (uncoated) • Serum separator tubes • 2K43 ARCHITECT STAT Myoglobin Reagent Kit
Plasma • Lithium Heparin • Lithium Heparin Materials Required but not Provided
• Plasma separator tubes • Plasma separator tubes with • ARCHITECT i System with STAT protocol capability
with lithium heparin lithium heparin • 3K51 ARCHITECT i - US - Addition B
• Sodium Heparin • 3K53 ARCHITECT i - WW (excluding US) - Addition B
• EDTA • 2K43-01 ARCHITECT STAT Myoglobin Calibrators
• 2K43-10 ARCHITECT STAT Myoglobin Controls
Other anticoagulants have not been validated for use with the ARCHITECT
STAT Myoglobin assay. • ARCHITECT i
• When serial specimens are being evaluated, the same type of • ARCHITECT i
specimen should be used throughout the study. • ARCHITECT i
• The ARCHITECT i System does not provide the capability to verify • ARCHITECT i
specimen type. It is the responsibility of the operator to verify the • ARCHITECT i
correct specimen types are used in the ARCHITECT STAT Myoglobin • ARCHITECT i
assay. • ARCHITECT i
Specimen Conditions • Pipettes or pipette tips (optional) to deliver the volumes specified on
• Do not use heat-inactivated specimens. the patient or control order screen.
• Performance has not been established using cadaver specimens or For information on materials required for maintenance procedures, refer
body fluids other than human serum or plasma. to the ARCHITECT System Operations Manual, Section 9.
• Specimens with obvious microbial contamination should not be
used.

3
Assay Procedure Specimen Dilution Procedures
• Before loading the ARCHITECT STAT Myoglobin Reagent Kit on the Specimens with a myoglobin value exceeding 1200.0 ng/mL will be
system for the first time, the microparticle bottle requires mixing to flagged as “>1200.0” and may be diluted with the Automated Dilution
resuspend microparticles that have settled during shipment. Protocol or the Manual Dilution Procedure.
• Invert the microparticle bottle 30 times. Automated Dilution Protocol
• Visually inspect the bottle to ensure microparticles are • If using the Automated Dilution Protocol, the system performs a
resuspended. If microparticles remain adhered to the bottle, 1:10 dilution of the specimen and automatically calculates the
continue inverting the bottle until the microparticles have been concentration of the specimen before dilution and reports the
completely resuspended. result.
• If the microparticles do not resuspend, DO NOT USE. Contact • Specimens with a myoglobin value exceeding 12000.0 ng/mL are
your local Abbott representative. flagged with the code “>12000.0” when run using the Automated
• Once the microparticles have been resuspended, remove and Dilution Protocol. These specimens may be diluted by following the
discard the cap. Wearing clean gloves, remove a septum from Manual Dilution Procedure.
the bag. Squeeze the septum in half to confirm that the slits are Manual Dilution Procedure
open. Carefully snap the septum onto the top of the bottle. • Manual dilutions should be performed as follows:
• Order calibration, if necessary. • The suggested dilution for a myoglobin test is 1:20.
• For information on ordering calibrations, refer to the ARCHITECT • Prior to diluting the specimen, dispense approximately 10 drops
System Operations Manual, Section 6. of ARCHITECT STAT Myoglobin Calibrator A into a clean test
• Order tests. tube for use in the next step.
• For information on ordering patient specimens and controls, • Transfer 190 μL of ARCHITECT STAT Myoglobin Calibrator A
refer to the ARCHITECT System Operations Manual, Section 5. from the test tube prepared in the prior step into another clean
• Load the ARCHITECT STAT Myoglobin Reagent Kit on the test tube and add 10 μL of the patient specimen.
ARCHITECT i System with STAT protocol capability. • The operator must enter the dilution factor in the Patient or
• Verify that all necessary assay reagents are present. Ensure that Control order screen. The system will use this dilution factor to
septums are present on all reagent bottles. automatically calculate the concentration of the sample before
• The minimum sample cup volume is calculated by the system and dilution. This will be the reported result. The dilution should
is printed on the Orderlist report. No more than 10 replicates may be performed so that the diluted result reads greater than
be sampled from the same sample cup. To minimize the effects of 40.0 ng/mL.
evaporation, verify adequate sample cup volume is present prior to • For detailed information on ordering dilutions, refer to the
running the test. ARCHITECT System Operations Manual, Section 5.
• Priority: 80 μL for the first ARCHITECT STAT Myoglobin test plus Calibration
30 μL for each additional ARCHITECT STAT Myoglobin test from • To perform an ARCHITECT STAT Myoglobin calibration, test the
the same sample cup. Calibrators A, B, C, D, E, and F in duplicate. A single sample of each
• ≤ 3 hours on board: 150 μL for the first ARCHITECT STAT ARCHITECT STAT Myoglobin Control level must be tested to evaluate
Myoglobin test plus 30 μL for each additional ARCHITECT STAT the assay calibration. Ensure that assay control values are within
Myoglobin test from the same sample cup. the concentration ranges specified in the control package insert.
• To minimize the effects of evaporation, all samples (patient Calibrators should be priority loaded.
specimens, calibrators and controls) must be tested within 3 hours • Calibration Range: 0.0 – 1200.0 ng/mL.
of being placed on board the ARCHITECT i System. • Once an ARCHITECT STAT Myoglobin calibration is accepted and
• If using primary or aliquot tubes, use the sample gauge to ensure stored, all subsequent samples may be tested without further
sufficient patient specimen is present. calibration unless:
• Prepare calibrators and controls. • A reagent kit with a new lot number is used.
• ARCHITECT STAT Myoglobin Calibrators and Controls should be • Controls are out of range.
prepared according to their respective package inserts. • For detailed information on how to perform an assay calibration,
• To obtain the recommended volume requirements for the refer to the ARCHITECT System Operations Manual, Section 6.
ARCHITECT STAT Myoglobin Calibrators, hold the bottles
vertically and dispense 8 drops of each calibrator into each QUALITY CONTROL PROCEDURES
respective sample cup. Dispense 150 μL of each control into The recommended control requirement for the ARCHITECT STAT
each respective sample cup. Myoglobin assay is that a single sample of each control level be tested
once every 24 hours each day of use. If laboratory quality control
• Load samples.
procedures require more frequent use of controls to verify test results,
• For information on loading samples, refer to the ARCHITECT follow those procedures.
System Operations Manual, Section 5.
The ARCHITECT STAT Myoglobin Control values must be within the
• Press RUN. The system performs the following functions: acceptable ranges specified in the control package insert. If a control is
• Moves the sample to the aspiration point. out of its specified range, the associated test results are invalid and must
• Loads a reaction vessel (RV) into the process path. be retested. Recalibration may be indicated.
• Aspirates and transfers sample into the RV. For detailed information on how to perform an assay calibration, refer to
• Advances the RV one position and transfers microparticles into the ARCHITECT System Operations Manual, Section 6.
the RV. Verification of Assay Claims
• Mixes, incubates, and washes the reaction mixture. For protocols to verify package insert claims, refer to the ARCHITECT
• Adds conjugate to the RV. System Operations Manual, Appendix B. The ARCHITECT STAT Myoglobin
• Mixes, incubates, and washes the reaction mixture. assay belongs to method group 1. Use ARCHITECT STAT Myoglobin
• Adds pre-trigger and trigger solutions. Calibrators in place of MasterCheck as described in the ARCHITECT
• Measures chemiluminescent emission to determine the quantity System Operations Manual, Appendix B.
of myoglobin in the sample.
• Aspirates contents of RV to liquid waste and unloads RV to solid
waste.
• Calculates the result.
• For optimal performance, it is important to follow the routine
maintenance procedures defined in the ARCHITECT System
Operations Manual, Section 9. If your laboratory requires more
frequent maintenance, follow those procedures.

4
RESULTS Mean
Calculation Conc.
The ARCHITECT STAT Myoglobin assay uses a 4 Parameter Logistic Instru- Reagent Value Within Run Total Run
Curve Fit (4PLC, Y-weighted) data reduction method to generate a Sample ment Lot n (ng/mL) SD % CV SD % CV
calibration curve. 1 A 80 56.9 2.0 3.6 2.2 3.9
Alternate Result Units B 80 56.7 1.9 3.4 2.0 3.5
• The default result unit for the ARCHITECT STAT Myoglobin assay Low C 80 62.3 2.2 3.5 2.6 4.2
is ng/mL. When the alternate result unit, μg/L, is selected, the Control 2 A 80 57.8 1.8 3.2 2.7 4.6
conversion factor used by the system is 1.0.
B 80 60.8 2.0 3.4 2.3 3.8
• Conversion Formula: (Concentration in ng/mL) x (1.0) = μg/L
C 80 60.1 2.3 3.8 2.4 3.9
Flags 1 A 80 324.9 13.3 4.1 15.1 4.6
• Some results may contain information in the Flags field. For a B 80 329.6 9.5 2.9 12.0 3.6
description of the flags that may appear in this field, refer to the
ARCHITECT System Operations Manual, Section 5. Medium C 80 353.0 11.0 3.1 12.8 3.6
Control 2 A 80 354.9 10.3 2.9 12.4 3.5
LIMITATIONS OF THE PROCEDURE
B 80 337.2 10.4 3.1 11.3 3.4
• For diagnostic purposes, the ARCHITECT STAT Myoglobin assay
results should be used in conjunction with other data; e.g., other C 80 337.6 12.0 3.6 12.7 3.8
clinical testing, ECG, symptoms, clinical observations, etc. 1 A 80 785.2 25.3 3.2 25.3 3.2
• Specimens from patients who have received preparations of mouse B 80 803.5 36.0 4.5 37.5 4.7
monoclonal antibodies for diagnosis or therapy may contain human C 80 848.1 29.3 3.5 32.9 3.9
anti-mouse antibodies (HAMA).12 Such specimens may show either High
Control 2 A 80 824.8 26.9 3.3 32.4 3.9
falsely elevated or depressed values when tested with assay kits that
B 80 813.3 29.6 3.6 32.7 4.0
employ mouse monoclonal antibodies.12,13 Although the ARCHITECT
STAT Myoglobin assay is specifically designed to minimize the effects C 80 821.7 38.3 4.7 44.8 5.4
of HAMA, assay results that are not consistent with other clinical 1 A 80 42.7 1.6 3.8 1.9 4.6
observations may require additional information for diagnosis. B 80 41.3 1.3 3.1 1.7 4.1
• Heterophilic antibodies in human serum can react with reagent C 80 45.7 2.0 4.5 2.2 4.8
immunoglobulins, interfering with in vitro immunoassays.14 The Low
MCC 2 A 80 42.6 1.7 3.9 2.7 6.3
presence of heterophilic antibodies in a patient specimen may cause
B 80 44.4 1.4 3.1 1.8 4.1
anomalous values to be observed.14 Additional information may be
required for diagnosis. C 80 44.7 2.1 4.6 2.3 5.1
• ARCHITECT STAT Myoglobin is not intended to be used on an 1 A 80 111.6 3.7 3.4 5.1 4.6
ARCHITECT i System without STAT protocol capability. B 80 110.1 4.4 4.0 4.7 4.3
EXPECTED VALUES C 80 118.5 4.6 3.9 5.3 4.5
Medium
It is recommended that each laboratory establish its own reference MCC 2 A 80 117.2 3.8 3.3 6.0 5.1
range, which may be unique to the population it serves depending upon B 80 114.3 2.9 2.5 4.1 3.6
geographical, dietary, or environmental factors. Serial sampling may be C 80 114.2 4.5 3.9 5.1 4.4
required to detect elevated levels. Any condition resulting in skeletal 1 A 80 297.1 12.6 4.2 15.5 5.2
or cardiac muscle damage can potentially increase myoglobin levels
B 80 293.2 12.9 4.4 13.4 4.6
above the expected value. A reference range study was conducted
based on guidance from the National Committee for Clinical Laboratory High C 80 312.6 13.8 4.4 15.6 5.0
Standards (NCCLS) Protocol C28-A2.15 Human plasma specimens MCC 2 A 80 320.7 7.4 2.3 14.5 4.5
from apparently healthy individuals were evaluated in replicates of one B 80 299.5 9.6 3.2 11.7 3.9
using the ARCHITECT STAT Myoglobin assay. The observed values are C 80 299.0 12.6 4.2 15.2 5.1
summarized in the following table.*
1 A 80 51.3 2.6 5.1 3.5 6.7
Population N 99th Percentile (ng/mL) B 80 49.7 2.8 5.7 3.5 6.9
Female 160 106.0 C 80 54.0 2.1 3.8 4.0 7.4
Male 159 154.9 Panel 1
2 A 80 51.2 1.5 2.9 3.1 6.1
TOTAL 319 140.1 B 80 53.4 2.2 4.2 2.9 5.4
* Representative data; results in individual laboratories may vary from C 80 52.3 2.5 4.8 3.3 6.3
these data. 1 A 80 116.6 3.8 3.3 6.3 5.4
SPECIFIC PERFORMANCE CHARACTERISTICS B 80 116.2 5.6 4.8 7.5 6.4
C 80 122.3 5.0 4.1 6.7 5.5
Precision Panel 2
The ARCHITECT STAT Myoglobin assay precision is ≤ 10% total CV 2 A 80 121.7 3.4 2.8 6.5 5.4
for samples ≥ 40.0 ng/mL. A study was performed for the ARCHITECT B 80 120.1 3.6 3.0 7.6 6.3
STAT Myoglobin assay with guidance from the NCCLS Protocol EP5-A.16 C 80 118.1 5.7 4.8 6.9 5.8
ARCHITECT STAT Myoglobin Controls, Cardiac Multiconstituent Controls
(MCC) and two human panels were assayed using three lots of reagents * Representative data; results in individual laboratories may vary from
in replicates of two at two separate times per day for 20 days on two these data.
instruments. Each reagent lot used a single calibration curve throughout Precision Profile
the study. Data from this study are summarized in the following table.* Precision profile testing was performed with guidance from the
International Federation of Clinical Chemistry and Laboratory Medicine
(IFCC).17 Human plasma panels ranging in concentration from
0.3 – 28.8 ng/mL were tested in replicates of two over 10 days on one
instrument using two reagent lots and three calibrations for a total of
40 replicates per panel. The total %CVs (combining variance components
for replicate, run, day and reagent lot) were calculated and plotted against
the mean concentration. A reciprocal curve was fitted through the data
and the 10% CV value was estimated as the concentration corresponding
to the 10% CV level of the fitted curve. The lowest ARCHITECT
STAT Myoglobin assay value exhibiting a 10% CV is 1.6 ng/mL.

5
Dilution Linearity Interference
The ARCHITECT STAT Myoglobin assay recovers diluted specimens Potential interference from elevated levels of bilirubin, hemoglobin,
within 20% of the expected result. A dilution linearity study was performed triglycerides, and total protein in the ARCHITECT STAT Myoglobin assay
evaluating ARCHITECT STAT Myoglobin using specimens with undiluted is ≤ 15% at the levels indicated in the following table. A study based
values that ranged between 300.1 and 1100.7 ng/mL. These specimens on guidance from the NCCLS Protocol EP7-A18 was performed for the
were diluted manually using normal human plasma at various dilution ARCHITECT STAT Myoglobin assay. Specimens with myoglobin levels
factors and representative percent recovery results are summarized in between 50.3 and 167.5 ng/mL were supplemented with the following
the following table.* potentially interfering compounds.
Mean Mean Potentially Interfering Potentially Interfering
Observed Endogenous Expected Substance Substance Concentration
Sample Dilution Value Value Value** % Bilirubin 20 mg/dL
ID Factor (ng/mL) (ng/mL) (ng/mL) Recovery*** Hemoglobin 500 mg/dL
1 undiluted 300.1 - - - Total Protein (Low) 4 g/dL
1:2 162.2 10.3 160.3 101 Total Protein (High) 10 g/dL
1:10 46.5 18.5 48.5 96 Triglycerides 1000 mg/dL
1:50 25.8 20.2 26.2 99
Evaluation of Other Potential Interferents
2 undiluted 796.4 - - -
Potential interference from HAMA and rheumatoid factor (RF) in the
1:2 404.3 21.4 419.6 96 ARCHITECT STAT Myoglobin assay is ≤ 15%. The ARCHITECT STAT
1:10 110.8 38.5 118.1 94 Myoglobin assay was evaluated by testing specimens with HAMA and RF
1:50 54.5 41.9 57.8 94 to further assess the clinical specificity. Specimens positive for HAMA
3 undiluted 1100.7 - - - and specimens positive for RF were evaluated for % interference with
myoglobin levels spiked between 107.5 and 174.5 ng/mL. Mean absolute
1:2 566.0 10.3 560.6 101
% interference is summarized in the following table.*
1:10 126.8 18.5 128.6 99
Other Potential Mean Absolute
1:50 42.0 20.2 42.2 100 Interferents Number of Specimens % Interference
* Representative data; results in individual laboratories may vary from HAMA Positive 10 7.7
these data. RF Positive 10 12.6
** Mean Expected Value includes endogenous myoglobin (ng/mL) found
in the normal human plasma. * Representative data; results in individual laboratories may vary from
these data.
Mean Observed Value (ng/mL)
*** % Recovery = x 100 Method Comparison
Mean Expected Value (ng/mL) The ARCHITECT STAT Myoglobin method comparison correlation
coefficient (r) is ≥ 0.90 when compared with AxSYM Myoglobin. The
Autodilution Verification method comparison slope is 1.0 ± 0.15. A study was performed where
Recovery performance was evaluated for the autodilution method of the lithium heparin plasma specimens were tested in replicates of one using
ARCHITECT STAT Myoglobin assay by testing specimens with undiluted ARCHITECT STAT Myoglobin over a period of three calibration cycles
values that ranged between 980.3 and 1170.3 ng/mL. The observed with three reagent lots on two instruments and compared with AxSYM
percent recovery results are summarized in the following table.* Myoglobin. Data from this study were analyzed using the Passing-
Mean Undiluted Mean Observed Bablok19 regression method and are summarized in the following table
Sample ID Value (ng/mL) Value (ng/mL) % Recovery** and scatter plot.*
1 1170.3 1148.8 98.2 ARCHITECT STAT Myoglobin vs. AxSYM Myoglobin
2 980.3 928.9 94.8 Regression Slope Intercept Correlation
3 1036.6 1010.8 97.5 Method n (95% CI) (95% CI) Coefficient (r)
4 1023.7 945.2 92.3 Passing- 0.987 2.738
234 0.989
5 1063.1 998.6 93.9 Bablok** (0.969 to 1.011) (1.959 to 3.338)

* Representative data; results in individual laboratories may vary from

these data.
Mean Observed Value (ng/mL)
** % Recovery = x 100
Mean Undiluted Value (ng/mL)
ARCHITECT STAT Myoglobin (ng/mL)

Analytical Sensitivity
The ARCHITECT STAT Myoglobin analytical sensitivity is ≤ 1.0 ng/mL at
the 95% level of confidence (n = 36 runs, 10 replicates of Calibrator A
and 4 replicates of Calibrator B per run). Analytical sensitivity is defined
as the concentration at two standard deviations above the ARCHITECT
STAT Myoglobin Calibrator A (0.0 ng/mL) grand mean and represents the
lowest concentration of myoglobin that can be distinguished from zero.
Analytical Specificity
The ARCHITECT STAT Myoglobin assay analytical specificity is ≤ 0.0001%
cross-reactivity with hemoglobin. A study based on guidance from NCCLS
Protocol EP7-A18 was performed using the ARCHITECT STAT Myoglobin
assay. Specificity of the assay was determined by studying the cross-
reactivity of hemoglobin in normal human plasma.*
Cross-Reactant
Cross-Reactant Concentration (ng/mL) % Cross-Reactivity AxSYM Myoglobin (ng/mL)
Hemoglobin 10,600,000 0.0001
Sample Range (ARCHITECT STAT Myoglobin): 7.6 - 1188.7 ng/mL
* Representative data; results in individual laboratories may vary from Sample Range (AxSYM Myoglobin): 7.6 - 990.9 ng/mL
these data. * Representative data; results in individual laboratories may vary from
these data.
** A linear regression method with no special assumptions regarding the
distribution of the samples and measurement errors.

6
BIBLIOGRAPHY
1. Vaidya H. Myoglobin. Lab Medicine May 1992;23(5):306–10.
2. Bhayana V, Henderson AR. Biochemical Markers of Myocardial
Damage. Clinical Biochemistry Feb 1995;28(1):1–29.
3. Rozenman Y, Gotsman M. The earliest diagnosis of acute myocardial
infarction. Annu Rev Med 1994;45:31–44.
4. Mair J, Morandell D, Genser N, et al. Equivalent early sensitivities
of myoglobin, creatine kinase MB mass, creatine kinase isoform
ratios, and cardiac troponins I and T for acute myocardial infarction.
Clin Chem 1995;41:1266–72.
5. Bhayana V, Cohoe S, Pellar TG, et al. Combination (multiple) testing
for myocardial infarction using myoglobin, creatine kinase-2 (mass),
and troponin T. Clinical Biochemistry 1994;27(5):395-406.
6. Zabel M, Hohnloser SH, Köster W, et al. Analysis of creatine
kinase, CK-MB, myoglobin, and troponin T time-activity curves for
early assessment of coronary artery reperfusion after intravenous
thrombolysis. Circulation 1993;87:1542–50.
7. Ellis AK, Little T, Masud ARZ, et al. Pattern of myoglobin release after
reperfusion of injured myocardium. Circulation 1985;72:639–47.
8. US Department of Labor, Occupational Safety and Health
Administration, 29 CFR Part 1910.1030, Occupational Exposure to
Bloodborne Pathogens.
9. US Department of Health and Human Services. Biosafety in
Microbiological and Biomedical Laboratories. 5th ed. Washington,
DC: US Government Printing Office, January 2007.
10. World Health Organization. Laboratory Biosafety Manual. Geneva:
World Health Organization, 2004.
11. Clinical and Laboratory Standards Institute. Protection of Laboratory
Workers from Occupationally Acquired Infections: Approved
Guideline - Third Edition. CLSI Document M29-A3. Wayne, PA:
Clinical and Laboratory Standards Institute, 2005.
12. Schroff RW, Foon KA, Beatty SM, et al. Human anti-murine
immunoglobulin responses in patients receiving monoclonal antibody
therapy. Cancer Res 1985;45:879–85.
13. Primus FJ, Kelley EA, Hansen HJ, et al. “Sandwich”-type immunoassay
of carcinoembryonic antigen in patients receiving murine monoclonal
antibodies for diagnosis and therapy. Clin Chem 1988;34:261–4.
14. Boscato LM and Stuart MC. Heterophilic antibodies: a problem for all
immunoassays. Clin Chem 1988;34(1):27-33.
15. National Committee for Clinical Laboratory Standards. How to
Define and Determine Reference Intervals in the Clinical Laboratory;
Approved Guideline – Second Edition. NCCLS Document C28-A2.
Wayne, PA: NCCLS, 2000.
16. National Committee for Clinical Laboratory Standards. Evaluation
of Precision Performance of Clinical Chemistry Devices – Approved
Guideline. NCCLS document EP5-A. Wayne, PA: NCCLS, 1999.
17. Panteghini M, Pagani F, Yeo K-TJ, et al. Evaluation of imprecision
for cardiac troponin assays at low-range concentrations. Clin Chem
2004;50(2):327-332.
18. National Committee for Clinical Laboratory Standards. Interference
Testing in Clinical Chemistry: Approved Guideline. NCCLS document
EP7-A. Wayne, PA: NCCLS, 2002.
19. Passing H, Bablok W. A new biometrical procedure for testing the
equality of measurements from two different analytical methods.
J Clin Chem Clin Biochem 1983;21:709-20.
ProClin is property of its owner.
Abbott Laboratories ABBOTT
Diagnostics Division Max-Planck-Ring 2
Abbott Park, IL 60064 USA 65205 Wiesbaden
Germany
+49-6122-580

Produced by Fisher Scientific, Middletown, VA 22645, USA for

Abbott Diagnostics Division

Distributed by Abbott Laboratories

Abbott Park, IL 60064 USA
ABBOTT
Diagnostics Division

November 2007
© 2004, 2007 Abbott Laboratories